Michael Goldberg

Michael Goldberg is Founder and CEO of Surge Therapeutics. Previously, he was a member of the faculty at Harvard Medical School and Dana-Farber Cancer Institute. Dr. Goldberg’s research has been published in Cell, Nature, Science, Nature Biotechnology, and Science Translational Medicine. Dr. Goldberg received his Hon. B.Sc. in Biological Chemistry from the University of Toronto, his M.Phil. in BioScience Enterprise from the University of Cambridge, and his Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology (MIT), where he also completed his post-doctoral training.